DK2970377T3 - Fremgangsmåder til fremstilling af et humant plasma-afledt igg-præparat beriget med hjernesygdom-relaterede naturlige igg'er - Google Patents

Fremgangsmåder til fremstilling af et humant plasma-afledt igg-præparat beriget med hjernesygdom-relaterede naturlige igg'er Download PDF

Info

Publication number
DK2970377T3
DK2970377T3 DK14721128.8T DK14721128T DK2970377T3 DK 2970377 T3 DK2970377 T3 DK 2970377T3 DK 14721128 T DK14721128 T DK 14721128T DK 2970377 T3 DK2970377 T3 DK 2970377T3
Authority
DK
Denmark
Prior art keywords
derivated
preparing
methods
human plasma
brain disease
Prior art date
Application number
DK14721128.8T
Other languages
English (en)
Inventor
Harald Arno Butterweck
Theresa Bauer
Alfred Weber
Wolfgang Teschner
Hans-Peter Schwarz
Lucia Gnauer
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Application granted granted Critical
Publication of DK2970377T3 publication Critical patent/DK2970377T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/027—Nanofiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2623—Ion-Exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK14721128.8T 2013-03-15 2014-03-14 Fremgangsmåder til fremstilling af et humant plasma-afledt igg-præparat beriget med hjernesygdom-relaterede naturlige igg'er DK2970377T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794378P 2013-03-15 2013-03-15
PCT/US2014/028953 WO2014144511A1 (en) 2013-03-15 2014-03-14 Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

Publications (1)

Publication Number Publication Date
DK2970377T3 true DK2970377T3 (da) 2020-01-27

Family

ID=50631072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14721128.8T DK2970377T3 (da) 2013-03-15 2014-03-14 Fremgangsmåder til fremstilling af et humant plasma-afledt igg-præparat beriget med hjernesygdom-relaterede naturlige igg'er

Country Status (12)

Country Link
US (5) US9556261B2 (da)
EP (2) EP3623377A1 (da)
AU (1) AU2013203043B2 (da)
DK (1) DK2970377T3 (da)
ES (1) ES2763396T3 (da)
HR (1) HRP20200035T1 (da)
HU (1) HUE047475T2 (da)
LT (1) LT2970377T (da)
PL (1) PL2970377T3 (da)
PT (1) PT2970377T (da)
SI (1) SI2970377T1 (da)
WO (1) WO2014144511A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201250247A (en) * 2011-04-01 2012-12-16 Baxter Int Use of cytokine levels in intravenous immunoglobulin treatment of Alzheimer's disease
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
KR101917196B1 (ko) * 2014-03-11 2018-11-09 주식회사 녹십자홀딩스 면역글로불린의 정제방법
CA2941232C (en) * 2014-03-11 2020-08-25 Green Cross Holdings Corporation Method for purifying immunoglobulin
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
SMT202100666T1 (it) * 2016-08-18 2022-01-10 Alkahest Inc Frazioni di plasma sanguigno come trattamento per disturbi cognitivi associati all'invecchiamento
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US20210154883A1 (en) * 2018-04-13 2021-05-27 Tricoya Technologies Ltd Acetylated Wood and Method of Making Same
RU2694620C1 (ru) * 2018-10-17 2019-07-16 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения и очистки иммуноглобулинов
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
BR112022000249A2 (pt) 2019-07-30 2022-05-17 Kindred Biosciences Inc Anticorpos de parvovírus para uso veterinário
EP4126930A1 (en) * 2020-03-31 2023-02-08 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
AU2021303496A1 (en) * 2020-07-10 2023-02-02 Grifols Worldwide Operations Limited Method for obtaining a composition comprising human plasma-derived immunoglobulin M
CN114736294B (zh) * 2022-04-24 2024-08-13 华兰生物工程重庆有限公司 一种破伤风免疫球蛋白的纯化方法及其亲和层析填料
US20250281530A1 (en) * 2022-05-02 2025-09-11 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4434093A (en) * 1982-07-26 1984-02-28 Ortho Diagnostic Systems Inc. Methods for preparation of HBs Ag free gamma globulins
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
DK0659767T4 (da) * 1993-12-27 2003-02-10 Zlb Bioplasma Ag Fremgangsmåde til fremstilling af et koncentrat af anti-D-immunoglobulin G og et farmaceutisk præparat, som indeholder dette
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
NZ509135A (en) 1998-06-09 2002-10-25 Statens Seruminstitut A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods
DK2270044T3 (da) * 1998-06-09 2015-01-26 Csl Behring Ag Flydende immunglobulin G (IgG) produkt
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
SI1543038T2 (sl) * 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
US20050221414A1 (en) * 2004-03-31 2005-10-06 Katalin Varadi Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
US20060099211A1 (en) * 2004-04-12 2006-05-11 Carmen Monthe Safer, more potent human immunoglobulin preparations for treating Alzheimer's disease
US7993580B2 (en) * 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
US8354249B2 (en) * 2005-08-11 2013-01-15 Omrix Biopharmaceuticals Ltd. Intravenous immunoglobulin composition
JP2010515717A (ja) 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
AU2008206923A1 (en) 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of Fc-containing proteins
EP2474322A1 (en) 2007-04-12 2012-07-11 Omrix Biopharmaceuticals Ltd. Products for prophylaxis and/or treatment of viral diseases and method of making and using same
US8466265B2 (en) * 2007-10-02 2013-06-18 Csl Limited Therapeutic antibody purification method and method of use
NZ585530A (en) * 2007-12-27 2012-06-29 Baxter Int Methods for differentiating plasma-derived protein from recombinant protein in a sample
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
US20100040601A1 (en) * 2008-06-10 2010-02-18 Cantin Edouard M Compositions and methods for treating herpes simplex virus infections and related diseases
FR2939667B1 (fr) * 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
MX2011012576A (es) 2009-05-27 2012-05-08 Baxter Int Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
US8796430B2 (en) * 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
RU2013121589A (ru) 2010-10-13 2014-11-20 Октафарма Аг Способ очистки фактора комплемента н
US20120183527A1 (en) * 2011-01-18 2012-07-19 Baxter International Inc. Measurement of anti-amyloid antibodies in human blood
TW201250247A (en) * 2011-04-01 2012-12-16 Baxter Int Use of cytokine levels in intravenous immunoglobulin treatment of Alzheimer's disease
IL212911A0 (en) 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
RU2014107743A (ru) 2011-07-29 2015-09-10 Илэвэн Байотерапьютикс, Инк. Очищенные белки
US9403899B2 (en) * 2011-08-26 2016-08-02 Baxalta Incorporated Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
AU2012321074B2 (en) * 2011-12-13 2015-12-03 Takeda Pharmaceutical Company Limited Measurement of autoantibodies at low conductivity conditions with increased sensitivity
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

Also Published As

Publication number Publication date
US20210054058A1 (en) 2021-02-25
ES2763396T3 (es) 2020-05-28
WO2014144511A1 (en) 2014-09-18
SI2970377T1 (sl) 2020-04-30
LT2970377T (lt) 2020-02-10
HRP20200035T1 (hr) 2020-10-30
HUE047475T2 (hu) 2020-04-28
EP2970377A1 (en) 2016-01-20
US9556261B2 (en) 2017-01-31
PL2970377T3 (pl) 2020-04-30
US20170218051A1 (en) 2017-08-03
US20260049127A1 (en) 2026-02-19
PT2970377T (pt) 2020-01-21
AU2013203043A1 (en) 2014-10-02
AU2013203043B2 (en) 2016-10-06
US10738107B2 (en) 2020-08-11
US20140271669A1 (en) 2014-09-18
US9896501B2 (en) 2018-02-20
US20140271679A1 (en) 2014-09-18
US12365723B2 (en) 2025-07-22
EP2970377B1 (en) 2019-12-04
EP3623377A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
DK2970377T3 (da) Fremgangsmåder til fremstilling af et humant plasma-afledt igg-præparat beriget med hjernesygdom-relaterede naturlige igg'er
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
DK3063159T3 (da) Fremgangsmåde til oprensning af et neutralt humant mælkeoligosaccharid ved hjælp af kromatografi med simuleret bevægeligt leje
IL244063A0 (en) A method for producing artificial teeth
IL241569B (en) Microarray for delivery of therapeutic agent and methods of use
SG11201504702XA (en) Removable lingual-vestibular dental alignment device and method for the production thereof
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
EP2982390A4 (en) MEDICAL DEVICE AND METHOD FOR PRODUCING A MEDICAL DEVICE
PL3005298T3 (pl) Sposób rekonstruowania obiektu na podstawie rzutowanych widoków
DK3065818T3 (da) Anordning til behandling af sygdomme i centralnervesystemet ved hjælp af sansestimulering
IL241235A0 (en) Nebulizer inhalation device for toddlers and patients with respiratory failure
EP3006058A4 (en) BLOOD FILTER AND METHOD FOR THE PRODUCTION THEREOF
EP3048471A4 (en) CHILDREN'S GLASSES AND MANUFACTURING PROCESS
DK2961426T3 (da) Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g
EP2900085A4 (en) PROCESS FOR PRODUCING NATURAL KOKUMI TASTE
SMT202000145T1 (it) Epitopi di proteina f di virus sinciziale respiratorio
EP2997929A4 (en) ZAHNERSATZARTIKULATOR
EP2943936A4 (en) METHOD AND DEVICE FOR VERTEX ERROR CORRECTION
DK3068403T3 (da) Fremgangsmåder til behandling af øjentilstande med et implantat med langvarig lægemiddelfrigivelse
IL240214B (en) A process for the preparation of enantiomerically enriched 3-aminopiperidine
DK3024816T3 (da) Ppar-sparende forbindelser til behandling af metaboliske sygdomme
DK2964185T3 (da) Præparater til behandlingen af søvnrelaterede luftvejslidelser
DK2991620T3 (da) Kombinationer af antipyrin og benzocain til behandling af sygdomme forbundet med en kranienerve
DK2943062T3 (da) Apparat og fremgangsmåde til udryddelse af invasive bjørnekloarter
DK3054996T3 (da) Fremgangsmåde til fremstilling af terapeutiske knoglemidler af høj renhed